不同病因的肝硬化患者肝细胞癌的风险：基于人群的队列研

StephenW

Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study
Authors

    First published: 1 February 2017Full publication history
    DOI: 10.1111/apt.13961View/save citation
    Cited by: 0 articles

    Article has an altmetric score of 47

    The Handling Editor for this article was Professor Peter Hayes, and it was accepted for publication after full peer-review.

Summary
Background

Among patients with cirrhosis, only those determined to be at risk for hepatocellular carcinoma (HCC) should undergo surveillance. However, little is known about how different aetiologies of cirrhosis affect risk for HCC.
Aim

To quantify the cumulative incidence of HCC among a representative population of people with cirrhosis of the liver of varying aetiology.
Methods

We identified subjects with hepatic cirrhosis from the UK's General Practice Research Database (1987–2006). Diagnoses of HCC were obtained from linked national cancer registries (1971–2006). Cox proportional hazards regression was used to estimate hazard ratios. The predicted 10-year cumulative incidence of HCC for each aetiology of cirrhosis was estimated while accounting for competing risks of death from any cause and liver transplant.
Results

Among 3107 people with cirrhosis, the adjusted relative risk of HCC was increased twofold to threefold among people with viral and autoimmune/metabolic aetiologies, compared to those with alcohol-associated cirrhosis. The 10-year predicted cumulative incidence estimates of HCC for each aetiology were alcohol, 1.2%; chronic viral hepatitis, 4.0%; autoimmune or metabolic disease, 3.2%; and cryptogenic, 1.1%.
Conclusions

In a population-based study in the UK, people with cirrhosis have an estimated cumulative 10-year incidence of HCC of 4% or lower. Cumulative incidence varies with aetiology such that individuals with alcohol or cryptogenic cirrhosis have the lowest risk for HCC. These findings provide important information for cost-effectiveness analyses of HCC surveillance.

StephenW

不同病因的肝硬化患者肝细胞癌的风险：基于人群的队列研究
作者

    首次发布：2017年2月1日完整的出版历史
    DOI：10.1111 / apt.13961查看/保存引文
    引用：0文章

    文章的测评分数为47

    这篇文章的处理编辑是Peter Hayes教授，它在完全同行评议后被接受出版。

概要
背景

在肝硬化患者中，只有那些被确定有肝细胞癌（HCC）风险的人才能接受监测。然而，很少知道肝硬化的不同病因如何影响HCC的风险。
目标

在不同病因的肝硬化患者的代表人群中量化肝癌的累积发病率。
方法

我们从英国通用实践研究数据库（1987-2006）确定了肝硬化的受试者。从连锁的国家癌症登记处（1971-2006）获得HCC的诊断。使用Cox比例风险回归来估计风险比。估计肝硬化的每个病因的HCC的预测的10年累积发病率，同时考虑任何原因和肝移植的死亡的竞争风险。
结果

在3107例肝硬化患者中，与具有酒精相关性肝硬化的患者相比，具有病毒和自身免疫/代谢病因的人的HCC的调整的相对风险增加了两倍至三倍。每个病因的HCC的10年预测累积发病率估计是酒精，1.2％;慢性病毒性肝炎，4.0％;自身免疫性或代谢性疾病，3.2％;和隐源性，1.1％。
结论

在英国的一项基于人群的研究中，肝硬化患者的HCC发病率估计累积为10％，为4％或更低。累积发生率随着病因学而变化，使得患有酒精或隐源性肝硬化的个体具有最低的HCC风险。这些发现为HCC监测的成本效益分析提供了重要信息。

菲凡

谢谢

jinpaimanman

肝硬化患者的HCC发病率估计累积为10％，为4％或更低,看来比国内台湾的数据要低

StephenW

回复 jinpaimanman 的帖子

慢性肝病毒性病因HCC 10年累积发病率为4％.  错误翻译.